Trial Outcomes & Findings for Proton Radiotherapy for Extremity Soft Tissue Sarcoma (NCT NCT01561495)

NCT ID: NCT01561495

Last Updated: 2019-12-06

Results Overview

Given this is initially a feasibility study- the primary measure is number of AEs (Adverse Events).

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

1 participants

Primary outcome timeframe

4 years

Results posted on

2019-12-06

Participant Flow

Participant milestones

Participant milestones
Measure
All Study Participants
All study participants received proton radiotherapy.
Overall Study
STARTED
1
Overall Study
COMPLETED
1
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Proton Radiotherapy for Extremity Soft Tissue Sarcoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Study Participants
n=1 Participants
All study participants received proton radiotherapy.
Age, Categorical
<=18 years
0 Participants
n=93 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=93 Participants
Age, Categorical
>=65 years
1 Participants
n=93 Participants
Sex: Female, Male
Female
0 Participants
n=93 Participants
Sex: Female, Male
Male
1 Participants
n=93 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=93 Participants
Race (NIH/OMB)
Asian
0 Participants
n=93 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=93 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=93 Participants
Race (NIH/OMB)
White
1 Participants
n=93 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=93 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=93 Participants
Region of Enrollment
United States
1 participants
n=93 Participants

PRIMARY outcome

Timeframe: 4 years

Population: Investigator and study team are unreachable after having left Penn despite multiple efforts to contact for more information- as such no data is available to present

Given this is initially a feasibility study- the primary measure is number of AEs (Adverse Events).

Outcome measures

Outcome data not reported

Adverse Events

All Study Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Susan Prendergast, RN

AbramsonCC Radiation Oncolocy

Phone: 215-662-4267

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place